Lipoprotein lipase (LPL) is a non-covalent, homodimeric, N-glycosylated enzyme important for metabolism of blood lipids. LPL is regulated by yet unknown post-translational events affecting the levels of active dimers. On co-expression of LPL with human molecular chaperones, we found that calreticulin had the most pronounced effects on LPL activity, but calnexin was also effective. Calreticulin caused a 9-fold increase in active LPL, amounting to about 50% of the expressed LPL protein. The total expression of LPL protein was increased less than 20%, and the secretion rates for active and inactive LPL were not significantly changed by the chaperone. Thus, the main effect was an increased specific activity of LPL both in cells and media. Chromatography on heparin-Sepharose and sucrose density gradient centrifugation demonstrated that most of the inactive LPL was monomeric and that calreticulin promoted formation of active dimers. Higher oligomers of inactive LPL were present in cell extracts, but only monomers and dimers were secreted to the medium. Interaction between LPL and calreticulin was demonstrated, and the effect of the chaperone was prevented by castanospermine, an inhibitor of N-glycan glucose trimming. Our data indicate an important role of endoplasmic reticulum-based chaperones for the folding/ dimerization of LPL.
Lipoprotein lipase (LPL)1 hydrolyzes triglycerides in the circulating plasma lipoproteins, such as chylomicrons and very low density lipoproteins (1-3). The enzyme is produced and secreted mainly by adipocytes and muscle cells, but it is also produced in other cells such as macrophages and certain neurons. LPL is transported by yet unclear mechanisms to the vascular endothelium, where it is attached to cell surfaces through interaction with heparan sulfate proteoglycans (HSPG). The products of lipolysis are taken up for storage or oxidation in adjacent tissues. In addition, LPL can mediate internalization of intact lipoproteins by bridging them to cell surface receptors like the LDL receptor-like protein or HSPG.LPL, along with pancreatic lipase, hepatic lipase (HL), and endothelial lipase, belongs to the gene family of mammalian triglyceride lipases (2, 4). The three-dimensional structure of LPL has not yet been determined. Based on homology with pancreatic lipase, it has been proposed that LPL has two structurally distinct regions, a larger N-terminal domain containing the active site and a smaller C-terminal domain with other important functions, such as binding to lipids, LDL receptorlike protein, and HSPG (5, 6).Catalytically active LPL is a non-covalent, homodimeric glycoprotein (7, 8). In the rough endoplasmic reticulum (ER), human LPL is co-translationally glycosylated at amino acid residues Asn 43 and Asn 359 . Studies using site-directed mutagenesis and inhibitors of transport between ER and Golgi have shown that core glycosylation at residue Asn 43 is necessary for activation and release of LPL from the ER, but glycosylation at Asn 359 is not necessary (9 -11). A number of studies...